Female Health Company (The) (NASDAQ:VERU)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Wednesday. They presently have a $5.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 146.31% from the stock’s previous close.

A number of other research analysts have also commented on the company. Rodman & Renshaw began coverage on Female Health Company (The) in a research report on Wednesday, July 26th. They issued a “buy” rating and a $5.00 price objective on the stock. Zacks Investment Research upgraded Female Health Company (The) from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Wednesday, September 27th. Finally, ValuEngine upgraded Female Health Company (The) from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st.

Female Health Company (NASDAQ VERU) traded down 1.675% during mid-day trading on Wednesday, hitting $1.996. The stock had a trading volume of 153,427 shares. Female Health Company has a 1-year low of $0.72 and a 1-year high of $3.00. The stock has a 50 day moving average of $1.38 and a 200-day moving average of $1.15.

Female Health Company (The) (NASDAQ:VERU) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.05. Female Health Company (The) had a negative net margin of 42.02% and a negative return on equity of 16.78%. The firm had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $2.20 million. Equities research analysts predict that Female Health Company will post ($0.17) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reiterates “Buy” Rating for Female Health Company (The) (VERU)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-female-health-company-the-veru/1608159.html.

In other Female Health Company (The) news, Director Harry Fisch bought 34,250 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was bought at an average price of $1.51 per share, for a total transaction of $51,717.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mitchell Shuster Steiner bought 100,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were acquired at an average price of $1.63 per share, with a total value of $163,000.00. Following the transaction, the insider now directly owns 7,764,767 shares in the company, valued at approximately $12,656,570.21. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 146,975 shares of company stock worth $234,279. Corporate insiders own 10.90% of the company’s stock.

Female Health Company (The) Company Profile

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.